Emerging Applications of Metabolomics in Clinical Pharmacology

Abstract

Metabolic disturbances have been associated with many human diseases, including cancer, diabetes, and cardiovascular disease. Metabolomics, a rapidly growing member of the –omics family, investigates cellular metabolism by quantifying metabolites on a large scale and provides a link between metabolic pathways and the upstream genome that governs them. With the advances in analytical technologies, metabolomics is becoming a powerful tool for identifying diagnostic biomarkers of diseases, elucidating the pathological mechanisms, discovering novel drug targets, predicting drug responses, interpreting the mechanisms of drug action, as well as enabling precision treatment of patients. In this review, we highlight the recent advances of technologies and methodologies in metabolomics and their applications to the field of clinical pharmacology. Recent publications from 2013 to 2018 are covered in the review, and current challenges and potential future directions in the field are also discussed.

Emerging trends and challenges of population-based cardiology

“…Pharmacogenomics is an omics approach allowing to identify genomic variants determining the reactions Еще один омиксный подход -фармакогеномикапозволяет идентифицировать геномные варианты, определяющие реакции на лекарственные препараты, в то время как метаболомика выявляет биохимические особенности, ассоциированные с различными ответами на препараты и гетерогенностью заболеваний [7]. При этом метаболомику можно рассматривать как инструмент интеграции исследований ССЗ в континуум изучения других неинфекционных заболеваний, при которых метаболические нарушения являются общим фактором риска и патогенетическим механизмом.…”

“…to drugs, whereas metabolomics elucidates biochemical features associated with different responses to drugs and disease heterogeneity [7]. In this, metabolomics can be viewed as a tool for integration of cardiovascular research into a continuum of studies focusing on other non-communicable diseases where metabolic abnormalities represent an overlapping risk factor and pathogenetic mechanism.…”

The Age of Omics‐Driven Precision Medicine

“…2,13 The State of the Art review by Hu and colleagues describes a number of specific examples of which pharmacometabolomics was used to identify diagnostic and prognostic biomarkers of various diseases, elucidate disease mechanisms, identify novel drug targets, and predict drug response. 15…”

“…Hence, pharmacometabolomics can be used to predict how a patient with a specific metabolic profile may respond to a drug, determine off‐target effects, and identify early predictors of therapeutic efficacy . The State of the Art review by Hu and colleagues describes a number of specific examples of which pharmacometabolomics was used to identify diagnostic and prognostic biomarkers of various diseases, elucidate disease mechanisms, identify novel drug targets, and predict drug response …”

Genetics and Not Shared Environment Explains Familial Resemblance in Adult Metabolomics Data

“…The metabolome is downstream of gene transcription, protein translation and protein function; therefore, metabolites are close to observable phenotypes in health and disease (Draisma et al, 2013;Goodacre et al, 2004). Metabolomics has been successful in identifying disease biomarkers, unraveling biological mechanisms, and for drug discovery and development (Pang et al, 2019).…”